Coherus announces positive Phase II results for cancer treatment
6 days ago · Coherus BioSciences announced the final data from its Phase II clinical trial. The trial evaluated casdozokitug (casdozo), a selective Interleukin-27-targeting antibody. It was tested …
LB Pharmaceuticals announces positive schizophrenia trial data
Jan 15, 2025 · LB Pharmaceuticals, a clinical-stage biopharmaceutical company focused on psychiatric disease therapies, announced positive results from its Phase II NOVA 1 trial of LB …
New study explores safer antidepressants for pregnant women
Jan 27, 2025 · Mark Ansorge, PhD, is an associate professor in the Department of Psychiatry at Columbia University.. He runs a research lab studying developmental origins and circuit …
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
Jun 18, 2024 · Mike Holmes, PhD, Chief Scientific Officer at Tessera Therapeutics. Michael joined Tessera in December 2021 as Chief Scientific Officer. Dr Holmes has over 20 years of …
New AI model may enable more targeted prostate cancer treatment
Oct 30, 2024 · The researchers demonstrated that the AI model could locate and measure around 85 percent of prostate tumours that had a Prostate Imaging Reporting and Data System (PI …
FDA greenlights AI-developed drug targeting solid tumors
Dec 4, 2024 · Phase I clinical trials on the horizon. With IND clearance secured, Insilico Medicine plans to initiate Phase I trials to evaluate ISM5939’s safety, tolerability, pharmacokinetics, and …
Drug candidates with blockbuster potential for CNS diseases
Sep 19, 2024 · Based on the positive efficacy and safety data generated in Phase I and II, the plan is to initiate a Phase III programme for mesdopetam. Following successful interactions at …
Drug Target Review: Leading Research & Insights in Drug Discovery
Stay at the forefront of drug discovery and therapeutic development with Drug Target Review. Dive into the latest research, industry analysis and technological advancements. Connect with …
Podcasts Archive - Drug Target Review
Aug 27, 2024 · Highlights of the AAPS 2024 Summer Scientific Forum. 21 October 2024 | By Drug Target Review. In this episode, we discuss the history of the AAPS Summer Scientific Forum, …
Game-changing pan-TEAD inhibitor for solid tumours - Drug …
Jun 12, 2023 · What is the potential therapeutic target of ISM6331 in the treatment of advanced solid tumours? Transcriptional enhanced associate domain (TEAD) proteins, a family including …